Romeo Power, Inc. (RMO, RMO.WT) Made Misstatements Regarding its Ability to Meet Demand      On October 5, 2020, RMG Acquisition Corp., a special purpose acquisition company, announced a definitive agreement

SelectQuote, Inc.  (SLQT) Failed to Disclose Underperformance of its PDP Products     During the class period, SelectQuote failed to disclose to investors that its 2019 cohort was underperforming.  On May

ATI Physical Therapy, Inc.  (ATIP) Made Misleading Statements Regarding its Business, Operations, and Prospects     Fortress Value Acquisition Corp. II was a special purpose acquisition company that went public in

Yalla Group Limited (YALA) Overstated its User Metrics and Revenue      Yalla Group Limited held its U.S. initial public offering (“IPO”) on September 29, 2020.   The Registration Statement in support

Live Ventures Inc. (LIVE) Made Misleading Statements Regarding its Business, Operations, and Prospects     During the class period, defendants made materially false and misleading statements and failed to disclose a

ContextLogic Inc. (WISH) Made Misstatements Regarding Key Metrics in its IPO Registration Statement      On December 16, 2020, ContectLogic completed its IPO, selling 46 million shares of Class A common

Ardelyx Inc. (ARDX) Made Misleading Statements in its Registration Statement in Connection with its Initial Public Offering   Defendants submitted a New Drug Application (NDA) to the U.S. Food and

AdaptHealth Corp. (AHCO) Made Misleading Statements Regarding its Business Prospects    On July 8, 2019, DFB, a special purpose acquisition company, announced it had entered into a definitive merger agreement

Iterum Therapeutics plc (ITRM) Made Misleading Statements Regarding its Drug Candidate     Iterum is developing sulopenem, an anti-infective compound with oral and intravenous formulations that is in Phase III clinical